Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres.

Riccardi N, Alagna R, Saderi L, Ferrarese M, Castellotti P, Mazzola E, De Lorenzo S, Viggiani P, Udwadia Z, Besozzi G, Cirillo D, Sotgiu G, Codecasa L; for StopTB Italia Onlus Group.

BMC Infect Dis. 2019 Jun 28;19(1):564. doi: 10.1186/s12879-019-4211-0.

2.

Replicative DNA polymerases promote active displacement of SSB proteins during lagging strand synthesis.

Cerrón F, de Lorenzo S, Lemishko KM, Ciesielski GL, Kaguni LS, Cao FJ, Ibarra B.

Nucleic Acids Res. 2019 Jun 20;47(11):5723-5734. doi: 10.1093/nar/gkz249.

3.

An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone.

Rizzo A, Palloni A, Frega G, Abbati F, De Lorenzo S, Brocchi S, Brandi G.

Anticancer Drugs. 2019 Apr;30(4):428-430. doi: 10.1097/CAD.0000000000000761.

PMID:
30875350
4.

Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments.

Tavolari S, Deserti M, Vasuri F, Curti S, Palloni A, Pinna AD, Cescon M, Frega G, De Lorenzo S, Barbera MA, Garajova I, Ricciardiello L, Malvi D, D'Errico-Grigioni A, Pantaleo MA, Brandi G.

Eur J Cancer. 2019 Jan;106:160-170. doi: 10.1016/j.ejca.2018.11.005. Epub 2018 Dec 5.

5.

An update of treatments of hepatocellular carcinoma in patients refractory to sorafenib.

Ielasi L, Sansone V, Granito A, Benevento F, De Lorenzo S, Tovoli F.

Drugs Today (Barc). 2018 Oct;54(10):615-627. doi: 10.1358/dot.2018.54.10.2880176. Review.

PMID:
30398482
6.

Dynamics of individual molecular shuttles under mechanical force.

Naranjo T, Lemishko KM, de Lorenzo S, Somoza Á, Ritort F, Pérez EM, Ibarra B.

Nat Commun. 2018 Oct 30;9(1):4512. doi: 10.1038/s41467-018-06905-8.

7.

The Italian registry of pulmonary non-tuberculous mycobacteria - IRENE: the study protocol.

Aliberti S, Codecasa LR, Gori A, Sotgiu G, Spotti M, Di Biagio A, Calcagno A, Nardini S, Assael BM, Tortoli E, Besozzi G, Ferrarese M, Matteelli A, Girardi E, De Lorenzo S, Seia M, Gramegna A, Del Prato B, Terranova L, Oriano M, Sverzellati N, Mirsaeidi M, Chalmers JD, Haworth CS, Loebinger MR, Aksamit T, Winthrop K, Ringshausen FC, Previdi G, Blasi F; IRENE Network.

Multidiscip Respir Med. 2018 Aug 9;13(Suppl 1):33. doi: 10.1186/s40248-018-0141-8. eCollection 2018.

8.

Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept.

De Lorenzo S, Tovoli F, Barbera MA, Garuti F, Palloni A, Frega G, Garajovà I, Rizzo A, Trevisani F, Brandi G.

Sci Rep. 2018 Jul 3;8(1):9997. doi: 10.1038/s41598-018-28337-6.

9.

Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases.

Brandi G, Venturi M, De Lorenzo S, Garuti F, Frega G, Palloni A, Garajovà I, Abbati F, Saccoccio G, Golfieri R, Pantaleo MA, Barbera MA.

Cancer Commun (Lond). 2018 Jun 26;38(1):41. doi: 10.1186/s40880-018-0312-1.

10.

Single-Stranded Condensation Stochastically Blocks G-Quadruplex Assembly in Human Telomeric RNA.

Gutiérrez I, Garavís M, de Lorenzo S, Villasante A, González C, Arias-Gonzalez JR.

J Phys Chem Lett. 2018 May 17;9(10):2498-2503. doi: 10.1021/acs.jpclett.8b00722. Epub 2018 Apr 27.

PMID:
29688724
11.

Regorafenib for the treatment of hepatocellular carcinoma.

Tovoli F, Granito A, De Lorenzo S, Bolondi L.

Drugs Today (Barc). 2018 Jan;54(1):5-13. doi: 10.1358/dot.2018.54.1.2736667. Review.

PMID:
29569657
12.

Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation.

Trevisani F, Brandi G, Garuti F, Barbera MA, Tortora R, Casadei Gardini A, Granito A, Tovoli F, De Lorenzo S, Inghilesi AL, Foschi FG, Bernardi M, Marra F, Sacco R, Di Costanzo GG.

J Cancer Res Clin Oncol. 2018 Feb;144(2):403-414. doi: 10.1007/s00432-017-2556-6. Epub 2017 Dec 16.

PMID:
29249005
13.

Brain Metastases from Biliary Tract Cancer: A Monocentric Retrospective Analysis of 450 Patients.

Frega G, Garajová I, Palloni A, Barbera MA, Trossello Pastore M, Faccioli L, Spinardi L, De Lorenzo S, Cubelli M, Pantaleo MA, Biasco G, Brandi G.

Oncology. 2018;94(1):7-11. doi: 10.1159/000479929. Epub 2017 Oct 13.

PMID:
29024931
14.

Recent Advances in Decellularization and Recellularization for Tissue-Engineered Liver Grafts.

Wang Y, Nicolas CT, Chen HS, Ross JJ, De Lorenzo SB, Nyberg SL.

Cells Tissues Organs. 2017;204(3-4):125-136. doi: 10.1159/000479597. Epub 2017 Oct 4. Review.

PMID:
28972946
15.

The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation.

Ravaioli M, Cucchetti A, Pinna AD, De Pace V, Neri F, Barbera MA, Maroni L, Frega G, Palloni A, De Lorenzo S, Ripoli MC, Pantaleo MA, Cescon M, Del Gaudio M, Brandi G.

Sci Rep. 2017 Sep 12;7(1):11305. doi: 10.1038/s41598-017-11810-z.

16.

Oral oxycodone/naloxone for pain control in cirrhosis: Observational study in patients with symptomatic metastatic hepatocellular carcinoma.

Tovoli F, De Lorenzo S, Samolsky Dekel BG, Piscaglia F, Benevento F, Brandi G, Bolondi L.

Liver Int. 2018 Feb;38(2):278-284. doi: 10.1111/liv.13546. Epub 2017 Sep 4.

PMID:
28792650
17.

Microbiota, NASH, HCC and the potential role of probiotics.

Brandi G, De Lorenzo S, Candela M, Pantaleo MA, Bellentani S, Tovoli F, Saccoccio G, Biasco G.

Carcinogenesis. 2017 Mar 1;38(3):231-240. doi: 10.1093/carcin/bgx007. Review.

PMID:
28426878
18.

Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients.

D'Arena G, Simeon V, Laurenti L, Cimminiello M, Innocenti I, Gilio M, Padula A, Vigliotti ML, De Lorenzo S, Loseto G, Passarelli A, Di Minno MND, Tucci M, De Feo V, D'Auria F, Silvestris F, Di Minno G, Musto P.

Leuk Lymphoma. 2017 Nov;58(11):2633-2641. doi: 10.1080/10428194.2017.1306648. Epub 2017 Apr 3.

PMID:
28367662
19.

Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy.

Codecasa LR, Toumi M, D'Ausilio A, Aiello A, Damele F, Termini R, Uglietti A, Hettle R, Graziano G, De Lorenzo S.

J Mark Access Health Policy. 2017 Feb 17;5(1):1283105. doi: 10.1080/20016689.2017.1283105. eCollection 2017.

20.

Cholangiocarcinoma: from risk to prevention?

Brandi G, De Lorenzo S, Tovoli F.

Transl Gastroenterol Hepatol. 2016 Jun 24;1:53. doi: 10.21037/tgh.2016.06.02. eCollection 2016. No abstract available.

21.

Recent Advances in Decellularization and Recellularization for Tissue-Engineered Liver Grafts.

Wang Y, Nicolas CT, Chen HS, Ross JJ, De Lorenzo SB, Nyberg SL.

Cells Tissues Organs. 2017;203(4):203-214. doi: 10.1159/000452761. Epub 2016 Dec 29. Review. Corrected and republished in: Cells Tissues Organs. 2017;204(3-4):125-136.

PMID:
28030865
22.

Aspirin for cholangiocarcinoma prevention: New targets to shift the dogma from ascertained risk to possible prevention.

Brandi G, De Lorenzo S, Palloni A, Biasco G, Tovoli F.

Hepatology. 2017 Mar;65(3):1075-1076. doi: 10.1002/hep.28999. Epub 2017 Feb 3. No abstract available.

PMID:
28010045
23.

In Reply.

Brandi G, Deserti M, Vasuri F, Farioli A, Degiovanni A, Palloni A, Frega G, Barbera MA, de Lorenzo S, Garajova I, Di Marco M, Pinna AD, Cescon M, Cucchetti A, Ercolani G, D'Errico-Grigioni A, Pantaleo MA, Biasco G, Tavolari S.

Oncologist. 2016 Dec;21(12):e5-e6. Epub 2016 Nov 2. No abstract available.

24.

Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.

Tiberi S, Sotgiu G, D'Ambrosio L, Centis R, Abdo Arbex M, Alarcon Arrascue E, Alffenaar JW, Caminero JA, Gaga M, Gualano G, Skrahina A, Solovic I, Sulis G, Tadolini M, Alarcon Guizado V, De Lorenzo S, Roby Arias AJ, Scardigli A, Akkerman OW, Aleksa A, Artsukevich J, Auchynka V, Bonini EH, Chong Marín FA, Collahuazo López L, de Vries G, Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Payen MC, Piana A, Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, Migliori GB.

Eur Respir J. 2016 Jun;47(6):1758-66. doi: 10.1183/13993003.00214-2016. Epub 2016 Apr 13.

25.

Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis?

Bolhuis MS, Tiberi S, Sotgiu G, De Lorenzo S, Kosterink JG, van der Werf TS, Migliori GB, Alffenaar JW.

Eur Respir J. 2016 Apr;47(4):1288-90. doi: 10.1183/13993003.02185-2015. No abstract available.

26.

Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients.

Brandi G, Deserti M, Vasuri F, Farioli A, Degiovanni A, Palloni A, Frega G, Barbera MA, de Lorenzo S, Garajova I, Di Marco M, Pinna AD, Cescon M, Cucchetti A, Ercolani G, D'Errico-Grigioni A, Pantaleo MA, Biasco G, Tavolari S; G.I.CO. (Gruppo Italiano Colangiocarcinoma).

Oncologist. 2016 May;21(5):600-7. doi: 10.1634/theoncologist.2015-0356. Epub 2016 Mar 31.

27.

Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.

Tiberi S, Payen MC, Sotgiu G, D'Ambrosio L, Alarcon Guizado V, Alffenaar JW, Abdo Arbex M, Caminero JA, Centis R, De Lorenzo S, Gaga M, Gualano G, Roby Arias AJ, Scardigli A, Skrahina A, Solovic I, Sulis G, Tadolini M, Akkerman OW, Alarcon Arrascue E, Aleska A, Avchinko V, Bonini EH, Chong Marín FA, Collahuazo López L, de Vries G, Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, Migliori GB.

Eur Respir J. 2016 Apr;47(4):1235-43. doi: 10.1183/13993003.02146-2015. Epub 2016 Mar 10.

28.

Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.

Tiberi S, Sotgiu G, D'Ambrosio L, Centis R, Arbex MA, Alarcon Arrascue E, Alffenaar JW, Caminero JA, Gaga M, Gualano G, Skrahina A, Solovic I, Sulis G, Tadolini M, Alarcon Guizado V, De Lorenzo S, Roby Arias AJ, Scardigli A, Akkerman OW, Aleksa A, Artsukevich J, Avchinko V, Bonini EH, Chong Marín FA, Collahuazo López L, de Vries G, Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Payen MC, Piana A, Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, Migliori GB.

Clin Infect Dis. 2016 May 1;62(9):1188-90. doi: 10.1093/cid/ciw088. Epub 2016 Feb 16. No abstract available.

PMID:
26908794
29.

Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis.

Brandi G, De Lorenzo S, Nannini M, Curti S, Ottone M, Dall'Olio FG, Barbera MA, Pantaleo MA, Biasco G.

World J Gastroenterol. 2016 Jan 14;22(2):519-33. doi: 10.3748/wjg.v22.i2.519. Review.

30.

Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience.

Tiberi S, D'Ambrosio L, De Lorenzo S, Viggiani P, Centis R, Sotgiu G, Alffenaar JW, Migliori GB.

Eur Respir J. 2016 Jan;47(1):333-6. doi: 10.1183/13993003.01278-2015. Epub 2015 Nov 19. No abstract available.

31.

Tuberculosis elimination, patients' lives and rational use of new drugs: revisited.

Tiberi S, D'Ambrosio L, De Lorenzo S, Viggiani P, Centis R, Migliori GB.

Eur Respir J. 2016 Feb;47(2):664-7. doi: 10.1183/13993003.01297-2015. Epub 2015 Nov 5. No abstract available.

32.

Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study.

Bolhuis MS, Tiberi S, Sotgiu G, De Lorenzo S, Kosterink JG, van der Werf TS, Migliori GB, Alffenaar JW.

Eur Respir J. 2015 Oct;46(4):1205-7. doi: 10.1183/13993003.00606-2015. Epub 2015 Jul 9. No abstract available.

33.

A Temperature-Jump Optical Trap for Single-Molecule Manipulation.

de Lorenzo S, Ribezzi-Crivellari M, Arias-Gonzalez JR, Smith SB, Ritort F.

Biophys J. 2015 Jun 16;108(12):2854-64. doi: 10.1016/j.bpj.2015.05.017.

34.

Feasibility and efficacy of dose-dense and dose-intense ABVD for high-risk patients with advanced Hodgkin lymphoma.

D'Arco AM, Califano C, Barone L, Belsito Petrizzi V, Iovino V, Langella M, Maglione V, Rivellini F, De Lorenzo S.

Br J Haematol. 2015 Nov;171(4):662-5. doi: 10.1111/bjh.13429. Epub 2015 Apr 14. No abstract available.

PMID:
25873239
35.

Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib.

Brandi G, De Lorenzo S, Di Girolamo S, Bellentani S, Saccoccio G, Biasco G.

Tumori. 2015 Apr 28;101(2):e46-8. doi: 10.5301/je.5000247.

PMID:
25702656
36.

Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia.

Ceppi F, Langlois-Pelletier C, Gagné V, Rousseau J, Ciolino C, De Lorenzo S, Kevin KM, Cijov D, Sallan SE, Silverman LB, Neuberg D, Kutok JL, Sinnett D, Laverdière C, Krajinovic M.

Pharmacogenomics. 2014 Jun;15(8):1105-16. doi: 10.2217/pgs.14.68.

37.

Bond elasticity controls molecular recognition specificity in antibody-antigen binding.

Alemany A, Sanvicens N, de Lorenzo S, Marco MP, Ritort F.

Nano Lett. 2013 Nov 13;13(11):5197-202. doi: 10.1021/nl402617f. Epub 2013 Oct 2.

PMID:
24074342
38.

The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells.

De Lorenzo SB, Patel AG, Hurley RM, Kaufmann SH.

Front Oncol. 2013 Sep 11;3:228. doi: 10.3389/fonc.2013.00228. Review.

39.

Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use.

Tiberi S, De Lorenzo S, Centis R, Viggiani P, D'Ambrosio L, Migliori GB.

Eur Respir J. 2014 Jan;43(1):289-92. doi: 10.1183/09031936.00122313. Epub 2013 Aug 29. No abstract available.

40.

Electrostatic binding and hydrophobic collapse of peptide-nucleic acid aggregates quantified using force spectroscopy.

Camunas-Soler J, Frutos S, Bizarro CV, de Lorenzo S, Fuentes-Perez ME, Ramsch R, Vilchez S, Solans C, Moreno-Herrero F, Albericio F, Eritja R, Giralt E, Dev SB, Ritort F.

ACS Nano. 2013 Jun 25;7(6):5102-13. doi: 10.1021/nn4007237. Epub 2013 Jun 3.

PMID:
23706043
41.

Tuberculosis a re-emerging disease.

De Lorenzo S, Tiberi S.

Intern Emerg Med. 2012 Oct;7 Suppl 3:S185-7. doi: 10.1007/s11739-012-0822-9.

PMID:
23073855
42.

Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB.

De Lorenzo S, Alffenaar JW, Sotgiu G, Centis R, D'Ambrosio L, Tiberi S, Bolhuis MS, van Altena R, Viggiani P, Piana A, Spanevello A, Migliori GB.

Eur Respir J. 2013 Jun;41(6):1386-92. doi: 10.1183/09031936.00124312. Epub 2012 Sep 20.

43.

Availability of anti-tuberculosis drugs in Europe.

Sotgiu G, D'Ambrosio L, Centis R, Bothamley G, Cirillo DM, De Lorenzo S, Guenther G, Kliiman K, Muetterlein R, Spinu V, Villar M, Zellweger JP, Sandgren A, Huitric E, Lange C, Manissero D, Migliori GB.

Eur Respir J. 2012 Aug;40(2):500-3. doi: 10.1183/09031936.00009212. No abstract available.

44.

Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.

Sotgiu G, Centis R, D'Ambrosio L, Alffenaar JW, Anger HA, Caminero JA, Castiglia P, De Lorenzo S, Ferrara G, Koh WJ, Schecter GF, Shim TS, Singla R, Skrahina A, Spanevello A, Udwadia ZF, Villar M, Zampogna E, Zellweger JP, Zumla A, Migliori GB.

Eur Respir J. 2012 Dec;40(6):1430-42. doi: 10.1183/09031936.00022912. Epub 2012 Apr 10. Review.

45.

On linezolid efficacy and tolerability.

De Lorenzo S, Centis R, D'Ambrosio L, Sotgiu G, Migliori GB.

Eur Respir J. 2012 Mar;39(3):770-2. doi: 10.1183/09031936.00116011. No abstract available.

46.

TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged?

Migliori GB, Sotgiu G, D'Ambrosio L, Centis R, Lange C, Bothamley G, Cirillo DM, De Lorenzo S, Guenther G, Kliiman K, Muetterlein R, Spinu V, Villar M, Zellweger JP, Sandgren A, Huitric E, Manissero D.

Eur Respir J. 2012 Mar;39(3):619-25. doi: 10.1183/09031936.00170411. Epub 2012 Feb 9.

47.

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.

Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH.

Clin Cancer Res. 2012 Mar 15;18(6):1655-62. doi: 10.1158/1078-0432.CCR-11-2890. Epub 2012 Jan 30.

48.

TB and M/XDR-TB infection control in European TB reference centres: the Achilles' heel?

Sotgiu G, D'Ambrosio L, Centis R, Bothamley G, Cirillo DM, De Lorenzo S, Guenther G, Kliiman K, Muetterlein R, Spinu V, Villar M, Zellweger JP, Sandgren A, Huitric E, Lange C, Manissero D, Migliori GB.

Eur Respir J. 2011 Nov;38(5):1221-3. doi: 10.1183/09031936.00029311. No abstract available.

49.

Improving signal/noise resolution in single-molecule experiments using molecular constructs with short handles.

Forns N, de Lorenzo S, Manosas M, Hayashi K, Huguet JM, Ritort F.

Biophys J. 2011 Apr 6;100(7):1765-74. doi: 10.1016/j.bpj.2011.01.071.

50.

Development of a standardised tool to survey MDR-/XDR-TB case management in Europe.

Sotgiu G, Centis R, D'ambrosio L, De Lorenzo S, D'arcy Richardson M, Lange C, Manissero D, Migliori GB; TBNET MDR-TB project.

Eur Respir J. 2010 Jul;36(1):208-11. doi: 10.1183/09031936.00186409. No abstract available.

Supplemental Content

Loading ...
Support Center